Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
6.27
+0.17 (2.79%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.08 - 6.30
52 week 4.60 - 11.72
Open 6.10
Vol / Avg. 1.30M/1.42M
Mkt cap 440.59M
P/E     -
Div/yield     -
EPS -0.79
Shares 70.27M
Beta 3.42
Inst. own 87%
Nov 14, 2017
Progenics Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 2, 2017
Q3 2017 Progenics Pharmaceuticals Inc Earnings Release
Nov 2, 2017
Q3 2017 Progenics Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -569.23% 15.46%
Operating margin -530.40% 18.87%
EBITD margin - 21.87%
Return on average assets -38.08% 6.50%
Return on average equity -91.48% 11.07%
Employees 58 -
CDP Score - -

Address

1 World Trade Ctr Fl 47
NEW YORK, NY 10007-0089
United States - Map
+1-646-9752500 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Mark R. Baker J.D., Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Patrick Fabbio Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Executive Vice President - Development
Age: 60
Bio & Compensation  - Reuters
Jeffrey D. Summer Senior Vice President - Strategy and Performance
Age: 57
Bio & Compensation  - Reuters
Bryce Tenbarge Vice President - Commercial
Age: 44
Bio & Compensation  - Reuters
Bradley L. Campbell Independent Director
Age: 41
Bio & Compensation  - Reuters
Karen Jean Ferrante M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Michael D. Kishbauch Independent Director
Age: 68
Bio & Compensation  - Reuters
David A. Scheinberg MD., Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters